
Caregivers reported itch, symptom, and QOL gains with roflumilast cream 0.05% in infants with AD; an FDA decision is due February 2027.
This has been an exciting year for medical office technology. Improvements in otoscopy, hemoglobin analyzers, tissue adhesives, and topical skin preps top the list of innovations.






